Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00798577 · ClinicalTrials.gov registry record · Phase 4
Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment
A Phase 4 study of Bacterial Conjunctivitis, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT00798577: Completed Phase 4 study of Bacterial Conjunctivitis, sponsored by Alcon Research.
NCT00798577 is a Phase 4 study of Bacterial Conjunctivitis that has completed, run by Alcon Research. The registered enrollment target is 24 participants, below the 621-participant average among 7 other Bacterial Conjunctivitis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00798577, a Phase 4 study of Bacterial Conjunctivitis, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to investigate the initial antibiotic effects in the treatment of bacterial conjunctivitis symptoms in subjects one year of age and older.
Primary Outcome
Photographs were taken before and after treatment. Outcome is the number of patients whose photographs showed a subjective visual change based upon an exploratory review of patient photographs in signs of bacterial conjunctivitis before and after treatment.
Conditions Studied
Interventions
- DRUG Vigamox Ophthalmic Solution
- DRUG BSS placebo
Study Locations (1)
Texas
- Contact Alcon Call Center For Trial Locations - Fort Worth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-02 |
| Phase | Phase 4 |
What the finished NCT00798577 record still lists
NCT00798577 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 621-participant average among 7 other Bacterial Conjunctivitis trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Bacterial Conjunctivitis appearing as the primary indexed condition, and to 2 interventions - of which Vigamox Ophthalmic Solution is the first listed.
NCT00798577 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00798577 about?
NCT00798577 is a clinical study titled "Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment". The primary objective of this study is to investigate the initial antibiotic effects in the treatment of bacterial conjunctivitis symptoms in subjects one year of age and older.
What is the current status of trial NCT00798577?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2008-10. Estimated completion is 2009-02.
What conditions does trial NCT00798577 study?
This clinical trial studies the following conditions: Bacterial Conjunctivitis.
What interventions are being tested in trial NCT00798577?
The interventions under investigation include: Vigamox Ophthalmic Solution (DRUG), BSS placebo (DRUG).
Who is sponsoring clinical trial NCT00798577?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00798577 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bacterial Conjunctivitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis
RECRUITING · Phase 3
-
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)
COMPLETED · Phase 3
-
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)
COMPLETED · Phase 3
-
AL-15469A for the Treatment of Bacterial Conjunctivitis
COMPLETED · Phase 3
-
Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis
COMPLETED · Phase 2
-
AL-15469A for the Treatment of Bacterial Conjunctivitis
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia